Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company MAKO Surgical (Nasdaq: MAKO ) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at MAKO and see what CAPS investors are saying about the stock right now.
MAKO facts
Headquarters (founded) | Fort Lauderdale, Fla. (2004) |
Market Cap | $609.5 million |
Industry | Healthcare equipment |
Trailing-12-Month Revenue | $96.2 million |
Management | Chairman/CEO Maurice Ferre CFO Fritz LaPorte |
Return on Equity (average, past 3 years) | (45.8%) |
Cash/Debt | $34.8 million / $0 |
Competitors | Biomet |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 1,203 members who have rated MAKO believe the stock will outperform the S&P 500 going forward.
Just last week, one of those bulls, fellow Fool David Meier (TMFHumbleServant), tapped MAKO as a tempting long-term turnaround opportunity:
The orthopedic surgery robot maker has had a rough go of it lately. The good thing is that they continue to make progress in attracting larger hospital systems to become customers. That will carry them over the next 5 years.If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future.
Our CAPS community gives MAKO a 4-star rating, but the recent market sell-off of its shares has many wondering whether its potential growth prospects make it a buy today or a stock to stay away from. Read our premium report to read up on the details of MAKO's story. Click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
No comments :
Post a Comment